Opinion: CRL benefits downtown Edmonton and the Education District
The CRL enables the City of Edmonton to invest in critical infrastructure and public spaces by leveraging future property tax revenues from new developments, rather than increasing the tax burden on current property owners. This approach has already helped fund improved streetscapes, utility upgrades, additional green space and enhanced walkability, all of which make downtown more attractive and accessible.
These investments have fuelled the growth of key community organizations and amenities, including arts, culture and entertainment venues. Major institutions like the Winspear Centre and the Oilers Entertainment Group have anchored downtown's renewal, while the CRL has created conditions for a diverse range of organizations to thrive. This resurgence draws people into the core, boosts local enterprise and builds community pride.
For MacEwan and NorQuest, the revitalization brings the Education District to life and supports broader social and economic goals. Together, we bring approximately 30,000 people downtown each day, with student populations projected to grow further by 2030. A welcoming, safe and lively city centre enhances learning, supports well-being, helps attract new talent and fosters continued development. The daily presence of our students energizes the core, strengthens local businesses and reinforces Edmonton's identity as a dynamic, education-focused urban hub.
We see this happening elsewhere. Recently, the City of Calgary allocated $9 million to the University of Calgary to relocate their School of Architecture, Planning and Landscape to a new downtown location, recognizing the significant impact of students, faculty and staff in energizing their downtown. As our student populations continue to grow, the need for accessible housing, public spaces and amenities will only increase — needs that the CRL is uniquely positioned to help address.
Looking ahead, extending the CRL will enable Edmonton to continue investing in projects that benefit everyone: new public spaces, support for entertainment and music, improved transit access and the remediation of underused land. These improvements support not only education and business, but also the arts, culture and community organizations that make downtown Edmonton a place where people want to live, learn and connect.
We encourage city leaders to recognize the value the CRL brings to all facets of downtown life and to support its continued use as a tool for building a stronger, more vibrant Edmonton.
Dr. Annette Trimbee is president and vice-chancellor of MacEwan University.
Carolyn Campbell is president and CEO of NorQuest College.
We invite you to write letters to the editor. A maximum of 150 words is preferred. Letters must carry a first and last name, or two initials and a last name, and include an address and daytime telephone number. All letters are subject to editing. We don't publish letters addressed to others or sent to other publications. Email: letters@edmontonjournal.com
Bookmark our website and support our journalism: Don't miss the news you need to know — add EdmontonJournal.com and EdmontonSun.com to your bookmarks and sign up for our newsletters here.
You can also support our journalism by becoming a digital subscriber. Subscribers gain unlimited access to The Edmonton Journal, Edmonton Sun, National Post and 13 other Canadian news sites. Support us by subscribing today: The Edmonton Journal |The Edmonton Sun.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
4 days ago
- Business Wire
Glaziers Have Ultra-Convenient Access to CRL and OBE Products With Opening of Five Innovative New Service Centers
DALLAS--(BUSINESS WIRE)--Glaziers now have a new, convenient way to access award-winning glazing products from C.R. Laurence Co. (CRL) and Oldcastle BuildingEnvelope, Inc. (OBE) all in one location. The two industry-leading companies are revolutionizing how glaziers get the products they need, saving them significant time and effort through an innovative one-stop-shopping model. CRL is substantially growing its presence in key markets by opening locations in Seattle, WA.; St. Louis, MO.; Cincinnati, OH; Tampa, FL; and Copenhagen, Denmark. The new North American service centers offer glaziers prompt access to a complete array of CRL hardware and supplies, OBE glass and US Aluminum and OBE glazing systems, as well as the expertise of staff trained to help glaziers select and successfully install a full range of product solutions. The CRL Denmark location marks a renewed commitment to serving our European customers and the start of an ambitious expansion program aimed at providing a comprehensive range of European appropriate glazing hardware solutions. 'We are transforming how we serve glaziers with our new integrated, customer-focused service centers,' explained Mark Adamson, CEO, Oldcastle BuildingEnvelope. 'Helping our customers be more efficient by bringing our products and services closer to them is driving our investment.' With this groundbreaking one-stop solution, CRL expands upon the companies' industry-leading footprint and prominent presence in North America, Europe, and Australia. The new facilities mark the start of a multi-year program of expansion driven by the Company's unwavering commitment to provide the best service, customer support, and locally available inventory. About Oldcastle BuildingEnvelope, Inc. Oldcastle BuildingEnvelope, Inc. is North America's leading vertically integrated manufacturer, fabricator and distributor of architectural hardware, glass and glazing systems. Headquartered in Dallas, Texas, OBE is a world-class building products company with significant presence in every major market in the U.S. and Canada. OBE manufactures high-performance architectural glass products and aluminum framing systems and distributes complementary hardware and glazing supplies. OBE delivers products to a broad customer base of architects, glaziers, contractors and developers serving diversified residential and commercial construction end-markets. For more information visit About CRL CRL is the industry's leading, full-service provider of architectural metals, glass fittings and professional-grade glazing supplies. The company leverages more than 50 years of experience and a track record of industry firsts to offer a one-stop shop with a breadth of innovative product choices, reliable service, and expert support from quote to completion. With manufacturing facilities, and sales, marketing, and service support in the United States, as well as dedicated sales and service centers in Canada, Europe, Australia, and the UK, CRL focuses on expanding opportunities for all to turn bold architectural visions into real world experiences. For more information visit

Associated Press
5 days ago
- Associated Press
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Capricor To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Capricor between October 9, 2024 and July 10, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - August 13, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Capricor Therapeutics, Inc. ('Capricor' or the 'Company') (NASDAQ: CAPR) and reminds investors of the September 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. [ This image cannot be displayed. Please visit the source: ] Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that defendants provided investors with material information concerning Capricor's lead cell therapy candidate drug deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Defendants' statements included, among other things, Capricor's ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration (FDA). Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel. On July 11, 2025, Capricor issued a press release announcing it received a Complete Response Letter (CRL) from the FDA denying the BLA specifically citing it did not meet the statutory requirement for substantial evidence of effectiveness and the need for additional clinical data. Further, the CRL referenced outstanding items in the Chemistry, Manufacturing, and Controls section of the application. Following this news, the price of Capricor stock declined from $11.40 per share on July 10, 2025 to $7.64 per share on July 11, 2025. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Capricor's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Capricor Therapeutics class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. To view the source version of this press release, please visit


Business Wire
06-08-2025
- Business Wire
Kirby McInerney LLP Reminds Capricor Therapeutics, Inc. (CAPR) Investors of Class Action Filing and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors who purchased Capricor Therapeutics, Inc. ('Capricor' or the 'Company') (NASDAQ:CAPR) securities to contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@ or fill out the contact form below, to discuss your rights or interests with respect to the securities fraud class action lawsuit against the Company. [ LEARN MORE ABOUT THE CLASS ACTION ] On May 5, 2025, Capricor issued a press release announcing it had completed its mid-cycle review meeting with the U.S. Food and Drug Administration (FDA) for its lead cell therapy candidate drug deramiocel. The Company announced that the review committee found no significant deficiencies and that the package was on track for a Prescription Drug User Fee Act (PDUFA) action date of August 31, 2025. The FDA confirmed its intent to hold an advisory committee meeting. On this news, the price of Capricor shares declined by approximately 29.13%, from $10.30 per share on May 5, 2025 to $7.30 per share on May 6, 2025. On July 11, 2025, Capricor announced that it received a Complete Response Letter (CRL) from the FDA denying the Company's Biologics License Application (BLA) for deramiocel. The CRL cited Capricor's failure to meet the requirement for evidence of effectiveness and the need for additional clinical data. Further, the CRL referenced outstanding items in the Chemistry, Manufacturing, and Controls section of the application. On this news, the price of Capricor stock declined from $11.40 per share on July 10, 2025 to $7.64 per share on July 11, 2025. According to the lawsuit, Capricor's statements regarding its ability to obtain a BLA for deramiocel from the FDA were misleading. The Company provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel. If you purchased or otherwise acquired Capricor securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@ or fill out the contact form below, to discuss your rights or interests with respect to these matters without any cost to you. [ CONTACT FORM ] Kirby McInerney LLP is a New York-based plaintiffs' law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm's efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP's website. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.